脑机接口医疗器械工作推进会召开；官方成立南极磷虾油事件调查组

Group 1: Medical Pricing and Regulation - The National Healthcare Security Administration (NHSA) issued the "Guidelines for the Project Establishment of Pathological Medical Service Pricing (Trial)" which consolidates existing pricing projects into 28 items, 3 additional charges, and 2 expansion items [1] - The NHSA will guide provincial healthcare security bureaus to establish unified pricing benchmarks, allowing for price adjustments based on these benchmarks [1] Group 2: Medical Device and Technology Development - The National Medical Products Administration (NMPA) held a meeting to advance brain-computer interface medical devices, emphasizing the importance of safety and effectiveness, and the need for innovative regulatory methods [2] - Aihong Pharmaceutical announced that its product APLD-2304 for bladder cancer diagnosis has had its registration application accepted by the EU, marking a significant step towards market entry [4] - Jin Dalai plans to invest 30 million yuan in Zhongke Hongtai Medical Technology, acquiring a 10% stake in the company focused on medical robotics [5] Group 3: Clinical Trials and Drug Development - Heng Rui Medicine received approval for clinical trials of SHR-2906 injection, a self-developed biopharmaceutical aimed at regulating metabolism and controlling weight [3] - Yuan Da Medicine reported positive results from a Phase III clinical trial of its innovative radioactive drug for prostate cancer diagnosis, indicating readiness for new drug application [9] Group 4: Market and Shareholder Activities - Duorui Medicine announced plans to sell up to 1.31% of its repurchased shares, with a total of 1,044,500 shares to be sold based on market prices [6][7] - Haoyuan Medicine's shareholder, Su Xin Fund, plans to reduce its stake by up to 0.26% due to financial needs, with a specified reduction period [8]